CXXC5 is highly expressed in PCa compared to normal prostate tissue, and high expression of CXXC5 is associated with poorer overall survival in PCa patients treated with AR signaling inhibitors, including ENZ and ABI [27, 92, 99]. The gene discussed is CXXC5; the disease is posterior cortical atrophy.